{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:35:01Z","timestamp":1785234901049,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immunotherapy with immune checkpoint inhibitors (mainly anti-PD1 and anti-PDL1 monoclonal antibodies) became a standard of care in non-small cell lung cancer (NSCLC) patients. Most of the clinical trials excluded patients with hepatitis B (HBV), hepatis C (HCV), and human immunodeficiency virus (HIV) active infection (<jats:xref>1<\/jats:xref>\u2013<jats:xref>10<\/jats:xref>). Despite the progress in treatment of these infections, they remain an unresolved clinical problem when lung cancer immunotherapy should be initiated in an NSCLC patient. This manuscript summarizes the data from the literature concerning this subgroup of patients including the rationale for immunotherapy initiation depending on the HBV, HCV, or HIV infection status; the risk of adverse events; and the efficacy compared to non-infected patients. One of the crucial questions is how the candidates to immunotherapy should be screened for HBV, HCV, and HIV infections. The year 2020 brought the world a new but dynamic viral problem\u2014severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). The incorporation of known data in oncology guidelines became a burning need, and then, which group of the infected patients can be treated with immunotherapy despite the infection. Oncologists should also know if these patients should receive antiviral therapy and what are the safe combinations in these settings. We also indicate which of the adverse events should be monitored carefully during checkpoint inhibitor treatment.<\/jats:p>","DOI":"10.3389\/fonc.2021.577514","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T07:15:46Z","timestamp":1628493346000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Viral Infection and Lung Cancer Immunotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Ewa","family":"Kalinka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Chmielewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Wojas-Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer Immunoediting From Immune Surveillance to Immune Escape","volume":"121","author":"Ryungsa","year":"2017","journal-title":"Immunology"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab Versus Docetaxel in Patients With Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Rando- Mised Controlled Trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab Versus Chemotherapy for PD-L1 Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Garassino Pembrolizumab Plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","unstructured":"FDA Approves Nivolumab Plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression \u22651%). FDA Website2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3390\/ijms20081915","article-title":"Beyond PD-L1 Markers for Lung Cancer Immunotherapy","volume":"20","author":"Wojas-Krawczyk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-Line Nivolumab Plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000434","article-title":"Safety and Efficacy of Anti-PD-1 Therapy for Metastatic Melanoma and Non-Small-Cell Lung Cancer in Patients With Viral Hepatitis: A Case Series","volume":"28","author":"Kothapalli","year":"2018","journal-title":"Melanoma Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors (ICIs) in Cancer Patients With HIV, Hepatitis B, or Hepatitis C Viral Infection","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.013","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Hepatitis B or Hepatitis C Infection","volume":"145","author":"Pertejo-Fernandez","year":"2020","journal-title":"Lung Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e001072","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV Reactivation in Patients With Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J ImmunoTherapy Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer\u2014A Phase 1 Study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","article-title":"Hepatitis B Virus Reactivation in Cancer Patients With Positive Hepatitis B Surface Antigen Undergoing PD-1 Inhibition","volume":"7","author":"Zhang","year":"2019","journal-title":"J ImmunoTherapy Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-20-19","article-title":"Reactivation of Hepatitis B Virus Among Patients With Cancer Receiving Immunotherapy","volume":"4","author":"Hwang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With HBV\/HCV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"99","author":"Pu","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.86761","article-title":"Hepatitis B Virus Screening in Patients With Non-Hodgkin Lymphoma in Clinical Practice in Poland \u2013 A Report of the Polish Lymphoma Research Group","volume":"16","author":"Kalinka","year":"","journal-title":"Arch Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0025","article-title":"Nivolumab Treatment in Advanced Lung Cancer Patient With Chronic Active Hepatitis C and Systemic Lupus Erythematosus","volume":"11","author":"Tagliamento","year":"2019","journal-title":"Immunotherapy"},{"key":"B26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical Characteristics of COVID-19-Infected Cancer Patients: A Retrospective Case Study in Three Hospitals Within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients With Cancer Appear More Vulnerable to SARS-COV-2: A Multi-Center Study During the COVID-19 Outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa102","article-title":"A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus","volume":"5","author":"Venkatesulu","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 Blockade on Severity of COVID-19 in Patients With Lung Cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in Patients With Thoracic Malignancies (TERAVOLT): First Results of an International, Registry-Based, Cohort Study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.007","article-title":"COVID-19 in Patients With Lung Cancer","volume":"331","author":"Luo","year":"2020","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41598-021-84137-5","article-title":"Oncologic Immunomodulatory Agents in Patients With Cancer and COVID-19","volume":"11","author":"Jee","year":"2021","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 Mortality in Patients With Cancer on Chemotherapy or Other Anticancer Treatments: A Prospective Cohort Study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0211","article-title":"Clinical Impact of COVID-19 in a Single-Center Cohort of a Prospective Study in Cancer Patients Receiving Immunotherapy","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1824646","DOI":"10.1080\/2162402X.2020.1824646","article-title":"Immunotherapy or Other Anti-Cancer Treatments and Risk of Exacerbation and Mortality in Cancer Patients With COVID-19: A Systematic Review and Meta-Analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Oncoimmunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e000933","DOI":"10.1136\/jitc-2020-000933","article-title":"COVID-19 and Immune Checkpoint Inhibitors: Initial Considerations","author":"Sullivan","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00286","article-title":"Management of Lung Cancer During the COVID-19 Pandemic","volume":"16","author":"Singh","year":"","journal-title":"JCO Oncol Pract"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.2018.36.15_suppl.3062","article-title":"A Six-Weekly (Q6W) Dosing Schedule for Pembrolizumab Based on an Exposure-Response (E-R) Evaluation Using Modeling and Simulation","volume":"36","author":"Lala","year":"2018","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e000984","DOI":"10.1136\/jitc-2020-000984","article-title":"Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management","volume":"8","author":"Naidoo","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e000952","DOI":"10.1136\/jitc-2020-000952","article-title":"Pneumonitis From Immune Checkpoint Inhibitors and COVID-19: Current Concern in Cancer Treatment","volume":"8","author":"Rossi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0300891620951863","article-title":"Interstitial Pneumontis in the COVID-19 Era: A Difficult Differential Diagnosis in Patients With Lung Cancer","volume":"107","author":"Catania","year":"2021","journal-title":"Tumori"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1817","article-title":"Priority COVID-19 Vaccination for Patients With Cancer While Vaccine Supply Is Limited","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00155-8","article-title":"Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients With Cancer Treated With Immune Checkpoint Inhibitors","volume":"22","author":"Waissengrin","year":"2021","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.critrevonc.2019.07.005","article-title":"Concomitant Medications During Immune Checkpoint Blockage in Cancer Patients: Novel Insights in This Emerging Clinical Scenario","volume":"142","author":"Rossi","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion Rates Following COVID-19 Vaccination Among Patients With Cancer","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00423","article-title":"Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars","volume":"6","author":"Jazieh","year":"","journal-title":"JCO Global Oncol"},{"key":"B47","unstructured":""}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.577514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T07:15:53Z","timestamp":1628493353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.577514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":47,"alternative-id":["10.3389\/fonc.2021.577514"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.577514","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"article-number":"577514"}}